{"id":52304,"date":"2025-12-31T10:56:02","date_gmt":"2025-12-31T02:56:02","guid":{"rendered":"https:\/\/flcube.com\/?p=52304"},"modified":"2025-12-31T10:56:03","modified_gmt":"2025-12-31T02:56:03","slug":"ribo-life-science-raises-hk1-6-billion-in-hong-kong-ipo-for-sirna-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52304","title":{"rendered":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline"},"content":{"rendered":"\n<p><strong>Suzhou Ribo Life Science Co., Ltd.<\/strong> (HKG: 6938) commenced trading on the <strong>Hong Kong Stock Exchange<\/strong> after raising approximately <strong>HK$1.6 billion<\/strong> (US$205\u202fmillion) through a global offering of <strong>27.5 million shares<\/strong> at <strong>HK$57.97 per share<\/strong>. The proceeds will accelerate development of its <strong>siRNA therapeutics pipeline<\/strong> targeting thrombotic and cardiometabolic diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-summary\">IPO Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Suzhou Ribo Life Science Co., Ltd. (6938.HK)<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>31\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Shares Issued<\/strong><\/td><td>27,487,400 shares (global offering)<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td>HK$57.97 per share<\/td><\/tr><tr><td><strong>Total Proceeds<\/strong><\/td><td>~HK$1.6 billion (US$205\u202fmillion)<\/td><\/tr><tr><td><strong>Market Cap (post\u2011IPO)<\/strong><\/td><td>~HK$6.4 billion (US$820\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\">Company Profile<\/h2>\n\n\n\n<p><strong>Founded<\/strong>: 2007 \u2013 18 years specializing in oligonucleotide therapeutics<br><strong>Focus<\/strong>: <strong>siRNA (small interfering RNA)<\/strong> drugs for chronic diseases<br><strong>Core Product<\/strong>: <strong>RBD4059<\/strong> \u2013 Factor XI (FXI)\u2011targeting siRNA for thrombotic diseases<br><strong>Pipeline<\/strong>: 7 in\u2011house discovered assets across 7 indications<br><strong>Phase 2 Assets<\/strong>: 4 candidates in cardiovascular, metabolic, renal, and liver diseases<br><strong>Differentiation<\/strong>: Proprietary GalNAc liver delivery platform with enhanced stability<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview\">Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Indication<\/th><th>Phase<\/th><th>Next Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>RBD4059<\/strong><\/td><td><strong>FXI<\/strong><\/td><td><strong>Thrombotic diseases<\/strong><\/td><td><strong>Phase 1\/2<\/strong><\/td><td><strong>Phase 2 data H2\u202f2026<\/strong><\/td><\/tr><tr><td>RBD2088<\/td><td>PCSK9<\/td><td>Hypercholesterolemia<\/td><td>Phase 2<\/td><td>Enrollment completion Q3\u202f2026<\/td><\/tr><tr><td>RBD3044<\/td><td>AGT<\/td><td>Hypertension<\/td><td>Phase 2<\/td><td>Interim analysis Q1\u202f2026<\/td><\/tr><tr><td>RBD4567<\/td><td>APOC3<\/td><td>Severe hypertriglyceridemia<\/td><td>Phase 2<\/td><td>IND filing EU Q4\u202f2026<\/td><\/tr><tr><td>RBD7890<\/td><td>HSD17B13<\/td><td>NASH<\/td><td>Phase 1<\/td><td>Phase 2 initiation 2027<\/td><\/tr><tr><td>RBD1023<\/td><td>TTR<\/td><td>ATTR amyloidosis<\/td><td>Phase 1<\/td><td>Patient dosing Q2\u202f2026<\/td><\/tr><tr><td>RBD1456<\/td><td>Undisclosed<\/td><td>Undisclosed<\/td><td>Discovery<\/td><td>IND filing 2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Thrombotic Diseases<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>China has <strong>3\u20114 million<\/strong> patients with venous thromboembolism annually<\/li>\n\n\n\n<li>FXI inhibition offers <strong>bleeding\u2011sparing anticoagulation<\/strong> vs. DOACs<\/li>\n\n\n\n<li>Market potential: <strong>\u00a58\u201110 billion<\/strong> by 2030<\/li>\n<\/ul>\n\n\n\n<p><strong>Cardiometabolic siRNA Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PCSK9<\/strong>, <strong>AGT<\/strong>, and <strong>APOC3<\/strong> targets represent <strong>\u00a515+ billion<\/strong> combined addressable market<\/li>\n\n\n\n<li>siRNA advantages: <strong>Q6M or annual dosing<\/strong> vs. monthly antibodies<\/li>\n\n\n\n<li>Patient compliance: Projected <strong>85\u201190%<\/strong> vs. <strong>60\u201165%<\/strong> for biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-use-of-proceeds\">Use of Proceeds<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Allocation<\/th><th>Amount (HK$ millions)<\/th><th>% of Total<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D &amp; Clinical Trials<\/strong><\/td><td>960<\/td><td>60%<\/td><\/tr><tr><td><strong>Manufacturing Scale\u2011up<\/strong><\/td><td>320<\/td><td>20%<\/td><\/tr><tr><td><strong>Commercial Infrastructure<\/strong><\/td><td>240<\/td><td>15%<\/td><\/tr><tr><td><strong>Working Capital &amp; General<\/strong><\/td><td>80<\/td><td>5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Core siRNA Asset<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Ribo Life<\/strong><\/td><td><strong>RBD4059 (FXI)<\/strong><\/td><td><strong>Phase 2<\/strong><\/td><td><strong>In\u2011house discovery, China\u2011focused<\/strong><\/td><\/tr><tr><td>Alnylam<\/td><td>Vutrisiran (ATTR)<\/td><td>Marketed<\/td><td>Global leader, premium pricing<\/td><\/tr><tr><td>Arrowhead<\/td><td>ARO\u2011APOC3 (hypertriglyceridemia)<\/td><td>Phase\u202f3<\/td><td>TRiM\u2122 delivery platform<\/td><\/tr><tr><td>Silence Therapeutics<\/td><td>SLN360 (cardiovascular)<\/td><td>Phase\u202f2<\/td><td>GalNAc\u2011conjugated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Advantage<\/strong>: Ribo Life\u2019s <strong>cost\u2011effective manufacturing<\/strong> and <strong>China regulatory expertise<\/strong> enable competitive pricing for domestic market penetration.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding Ribo Life Science\u2019s development pipeline, market penetration, and revenue forecasts. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52306,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4524,72,1725],"class_list":["post-52304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-6938","tag-ipo","tag-ribo-life-science"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52304\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52304\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-31T02:56:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-31T02:56:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline\",\"datePublished\":\"2025-12-31T02:56:02+00:00\",\"dateModified\":\"2025-12-31T02:56:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101.webp\",\"keywords\":[\"HKG: 6938\",\"IPO\",\"Ribo Life Science\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52304#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52304\",\"name\":\"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101.webp\",\"datePublished\":\"2025-12-31T02:56:02+00:00\",\"dateModified\":\"2025-12-31T02:56:03+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52304\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52304#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52304","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline","og_description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.","og_url":"https:\/\/flcube.com\/?p=52304","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-31T02:56:02+00:00","article_modified_time":"2025-12-31T02:56:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52304#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52304"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline","datePublished":"2025-12-31T02:56:02+00:00","dateModified":"2025-12-31T02:56:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52304"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52304#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","keywords":["HKG: 6938","IPO","Ribo Life Science"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52304#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52304","url":"https:\/\/flcube.com\/?p=52304","name":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52304#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52304#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","datePublished":"2025-12-31T02:56:02+00:00","dateModified":"2025-12-31T02:56:03+00:00","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock Exchange after raising approximately HK$1.6 billion (US$205\u202fmillion) through a global offering of 27.5 million shares at HK$57.97 per share. The proceeds will accelerate development of its siRNA therapeutics pipeline targeting thrombotic and cardiometabolic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52304#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52304"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52304#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","width":1080,"height":608,"caption":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52304#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52304"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52304\/revisions"}],"predecessor-version":[{"id":52307,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52304\/revisions\/52307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52306"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}